EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models

Renatta N Knox iD, Jocelyn O Eidahl, Lindsay M Wallace, Sarah G Choudury, Afrooz Rashnonejad iD, Katelyn Daman, Matthew J Guggenbiller, Nizar Y Saad iD, Michael E Hoover, Liwen Zhang, Owen E Branson, Charles P Emerson und 2 weitere

Annals of Neurology · 2023

DOI: 10.1002/ana.26668 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2023. Verfasst von Renatta N Knox und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIAMS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Facioscapulohumeral muscular dystrophy (FSHD) is caused by abnormal de‐repression of the myotoxic transcription factor DUX4. Although the transcriptional targets of DUX4 are known, the regulation of DUX4 protein and the molecular consequences of this regulation are unclear. Here, we used in vitro models of FSHD to identify and characterize DUX4 post‐translational modifications (PTMs) and their impact on the toxic function of DUX4.

Methods

We immunoprecipitated DUX4 protein and performed mass spectrometry to identify PTMs. We then characterized DUX4 PTMs and potential enzyme modifiers using mutagenesis, proteomics, and biochemical assays in HEK293 and human myoblast cell lines.

Results

We identified 17 DUX4 amino acids with PTMs, and generated 55 DUX4 mutants designed to prevent or mimic PTMs. Five mutants protected cells against DUX4‐mediated toxicity and reduced the ability of DUX4 to transactivate FSHD biomarkers. These mutagenesis results suggested that DUX4 toxicity could be counteracted by serine/threonine phosphorylation and/or inhibition of arginine methylation. We therefore sought to identify modifying enzymes that could play a role in regulating DUX4 PTMs. We found several enzymes capable of modifying DUX4 protein in vitro, and confirmed that protein kinase A (PKA) and protein arginine methyltransferase (PRMT1) interact with DUX4.

Interpretation

These results support that DUX4 is regulated by PTMs and set a foundation for developing FSHD drug screens based mechanistically on DUX4 PTMs and modifying enzymes. ANN NEUROL 2023;94:398–413

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralHumansGene Expression RegulationHEK293 CellsHomeodomain ProteinsMuscle, SkeletalProtein Processing, Post-TranslationalProtein-Arginine N-MethyltransferasesRepressor Proteins

Substanzen

Homeodomain ProteinsPRMT1 protein, humanProtein-Arginine N-MethyltransferasesRepressor ProteinsDUX4L1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Washington University School of Medicine, St. Louis, MO.
  • Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH.
  • Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
  • Wellstone Muscular Dystrophy Program, Department of Neurology, University of Massachusetts Chan Medical School, Worcester, MA.
  • Li Weibo Institute for Rare Disease Research, University of Massachusetts Chan Medical School, Worcester, MA.
  • Department of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH.

ORCID-Profile: Renatta N Knox, Afrooz Rashnonejad, Nizar Y Saad, Scott Q Harper

Förderung

  • NIH HHS
  • NIAMS NIH HHS
  • NICHD NIH HHS
  • NINDS NIH HHS
  • ODCDC CDC HHS
  • American Academy of Neurology
  • American Brain Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Knox, R. N., Eidahl, J. O., Wallace, L. M., Choudury, S. G., Rashnonejad, A., Daman, K., Guggenbiller, M. J., Saad, N. Y., Hoover, M. E., Zhang, L., Branson, O. E., Emerson, C. P., Freitas, M. A., & Harper, S. Q. (2023). Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models. Annals of Neurology. https://doi.org/10.1002/ana.26668

Vancouver

Knox RN, Eidahl JO, Wallace LM, Choudury SG, Rashnonejad A, Daman K, et al. Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models. Annals of Neurology. 2023. doi:10.1002/ana.26668

BibTeX
@article{Knox2023,
  author = {Knox, Renatta N and Eidahl, Jocelyn O and Wallace, Lindsay M and Choudury, Sarah G and Rashnonejad, Afrooz and Daman, Katelyn and Guggenbiller, Matthew J and Saad, Nizar Y and Hoover, Michael E and Zhang, Liwen and Branson, Owen E and Emerson, Charles P and Freitas, Michael A and Harper, Scott Q},
  title = {Post‐Translational Modifications of the DUX4 Protein Impact Toxic Function in FSHD Cell Models},
  journal = {Annals of Neurology},
  year = {2023},
  doi = {10.1002/ana.26668}
}
Kostenlos starten →